Back to Journals » Therapeutics and Clinical Risk Management » Call For Papers

Therapeutics and Clinical Risk Management

ISSN: 1178-203X

The following Article Collection/ Thematic Series is currently open for submissions:


Dove Medical Press is pleased to invite you to submit your research to an upcoming Thematic Series on "Asthma”, in Therapeutics and Clinical Risk Management, edited by our journal Editor in Chief Professor Garry Walsh.

Upon submission, please use the promo code DKPCL for 20% off the advertised article processing charge and indicate that your manuscript will be considered for the Thematic Series of “Asthma”. The deadline for manuscripts is the 31 July 2023.
For any inquiries, please email Jermaine Wilcock, Commissioning Editor at [email protected]

About the Thematic Series

Asthma remains a major cause of ill-health worldwide that presents as a heterogeneous, chronic inflammatory airways disorder characterized by complex and diverse inflammatory processes including goblet cell hyperplasia, airway smooth muscle hypertrophy and sub-epithelial fibrosis that give rise to airway hyperresponsiveness (AHR) and reversible airflow limitation. Asthma can be divided into ‘asthma phenotypes’ that take demographic, clinical and/or pathophysiological characteristics into account.

A further refinement involves division into disease entities termed ‘asthma endotypes’ based on specific pathophysiological mechanisms. For example, T helper 2 (TH2)-high asthma is seen in around 50% of patients who typically have eosinophilic inflammation mediated by cytokines including IL-4, IL-5 and IL-13. Elevated levels of immunoglobulin E (IgE) may also be present, while both Th2 and non-Th2 mechanisms contribute to asthma pathogenesis. Furthermore, respiratory viral infection is known to be a common risk factor for asthma exacerbations, although the underlying mechanisms require further investigation.

Most asthmatic patients achieve satisfactory symptom control using inhaled glucocorticosteroids and bronchodilators such as β2-adrenergic agonists, with the addition of oral leukotriene inhibitors if required. However, severe disease is seen in the region of 5% of asthmatic subjects who do not achieve satisfactory asthma control despite adherence to high dose inhaled or systemic glucocorticoid therapies giving rise to recurrent exacerbations and persistent symptoms together with significant morbidity, quality of life issues with attendant health cost implications.

This Special Thematic Issue of Therapeutics and Clinical Risk Management will address key aspects of the pathogenesis of asthma that informs diagnosis and treatment together with the development of more effective novel therapy for this important and common condition. The journal is seeking original submissions and review articles on the following topics related to:
• Current asthma therapy
• Severe asthma
• Paediatric asthma
• Co-morbidities; rhinitis; obesity, COPD
• COVID-19
• Viral infection
• The role of pro-inflammatory cells including T cells; mast cells; eosinophils; neutrophils; epithelial cells and smooth muscle cells
• Biomarkers
• Monoclonal antibody based biologic therapy (IgE; IL4/13; IL-5)

Submit your manuscript


View all papers in this thematic series

Call For Papers

Editor-in-Chief: Professor Garry Walsh

To see where Therapeutics and Clinical Risk Management is indexed online view the Journal Metrics

What is the advantage to you of publishing in Therapeutics and Clinical Risk Management?

  • It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
  • Although Therapeutics and Clinical Risk Management receives a large number of papers, unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
  • The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Therapeutics and Clinical Risk Management has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
  • Many authors have found that our peer reviewer’s comments substantially add to their final papers.

To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution an article publishing charge.

PubMed Central
Therapeutics and Clinical Risk Management is indexed on PubMed Central (title abbreviation: Ther Clin Risk Manag).  All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page.

Yours sincerely
Professor Garry Walsh
Therapeutics and Clinical Risk Management

Email: Editor-in-Chief